NVAX:NGS-Novavax Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 14.4

Change

0.00 (0.00)%

Market Cap

USD 0.34B

Volume

0.02B

Analyst Target

USD 227.60
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 122.24B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 115.08B
MRNA Moderna Inc

N/A

USD 51.07B
ARGX argenx NV ADR

N/A

USD 23.44B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 20.96B
BNTX BioNTech SE

N/A

USD 20.40B
BGNE BeiGene Ltd

N/A

USD 17.50B
GMAB Genmab AS

N/A

USD 16.65B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.98B
RPRX Royalty Pharma Plc

N/A

USD 15.90B

ETFs Containing NVAX

ULTY Tidal Trust II 5.67 % 0.00 %

N/A

USD 0.04B
GERM ETFMG Treatments Testing .. 4.63 % 0.00 %

N/A

USD 0.01B
CURE:AU ETFS S&P Biotech ETF 3.07 % 0.00 %

N/A

USD 0.04B
XBI SPDR® S&P Biotech ETF 2.80 % 0.35 %

N/A

USD 7.07B
BBC Virtus LifeSci Biotech Cl.. 2.12 % 0.79 %

N/A

USD 0.01B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 1.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 200.00% 97% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 200.00% 97% N/A 98% N/A
Trailing 12 Months  
Capital Gain 79.10% 90% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.10% 90% A- 94% A
Trailing 5 Years  
Capital Gain 182.35% 90% A- 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 182.35% 89% A- 89% A-
Average Annual (5 Year Horizon)  
Capital Gain 462.05% 96% N/A 98% N/A
Dividend Return 462.05% 96% N/A 98% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 988.03% 7% C- 3% F
Risk Adjusted Return 46.76% 92% A 77% C+
Market Capitalization 0.34B 92% A 83% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 12.89 39% 62%
Price/Book Ratio 49.52 3% 2%
Price / Cash Flow Ratio -3.73 58% 73%
Price/Free Cash Flow Ratio -0.53 38% 56%
Management Effectiveness  
Return on Equity -898.20% 10% 4%
Return on Invested Capital 120.60% 94% 97%
Return on Assets -16.32% 79% 28%
Debt to Equity Ratio -23.44% 80% 90%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector